Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial

被引：0
|
作者：
Shi, Qiyun
Qi, Xiaowei
Tang, Peng
Fan, Linjun
Chen, Li
Wang, Shushu
Zhang, Guozhi
Wang, Mengyuan
Che, Hongying
Lv, Pengwei
Chen, Dejie
Hu, Jinhui
Li, Qiuyun
Zhang, Yanwu
Yu, Qiao
Yang, Kunxian
Zhong, Yuan
Chen, Chuang
Zhou, Zemin
Qian, Liyuan
Zhang, Jingwei
Ma, Mingde
Sun, Yi
Liu, Jiangbo
Zhang, Yi
Jiang, Jun
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT2-22-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-22-01
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial
    Zhong, Xiaorong
    He, Ping
    Chen, Jie
    Yan, Xi
    Wei, Bin
    Zhang, Zhang
    Bu, Hong
    Li, Jing
    Tian, Tinglun
    Lv, Qing
    Wang, Xiaodong
    Li, Hongjiang
    Wang, Jing
    Huang, Juan
    Suo, Jiaojiao
    Liu, Xiaoxiao
    Zheng, Hong
    Luo, Ting
    GLAND SURGERY, 2022, 11 (01) : 216 - +
  • [42] Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study
    Jiang, Kuikui
    Hong, Ruoxi
    Xia, Wen
    Lu, Qianyi
    Li, Liang
    Huang, Jianhao
    Shi, Yanxia
    Yuan, Zhongyu
    Zheng, Qiufan
    An, Xin
    Xue, Cong
    Huang, Jiajia
    Bi, Xiwen
    Chen, Meiting
    Zhang, Jingmin
    Xu, Fei
    Wang, Shusen
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 513 - 521
  • [43] Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer : a multicenter, open-label, phase 2 trial
    Cao, F.
    Ma, Z.
    Hu, G.
    Zhu, X.
    Li, S.
    Chen, S.
    Chen, B.
    Li, Z.
    Wu, W.
    Ji, X.
    Shu, J.
    Tao, D.
    Hu, X.
    Zheng, M.
    Wang, O.
    Feng, Q.
    Hao, J.
    Li, X.
    BREAST, 2023, 68 : S16 - S16
  • [44] The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study
    Li, Fu
    Liang, Yimin
    Luo, Ming
    Shen, Jiayue
    Zhou, Taosheng
    Liang, Yajing
    Tang, Xiaoqi
    Yuan, Huiming
    Zeng, Jian
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [45] Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/trastuzumab) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial.
    Gao, Hong-Fei
    Wu, Zhiyong
    Lin, Ying
    Song, Xiangyang
    Cao, Yin
    Liu, Zhenzhen
    Chen, Qian-Jun
    Zhang, Liulu
    Yang, Ci-Qiu
    Yang, Mei
    Zhu, Teng
    Li, Jieqing
    Ji, Fei
    Cheng, Min-Yi
    Wang, Kun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Efficacy and safety of pyrotinib combined with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer (BC): A single-arm phase II trial.
    Hao, Chunfang
    Qi, Xiaowei
    Shi, Yehui
    Tong, Zhongsheng
    Zhang, Jie
    Meng, Wenjing
    Yang, Xiaonan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial
    Tokunaga, Shinya
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Kawajiri, Hidemi
    Tokumoto, Mao
    Nishimura, Shigehiko
    Nishimori, Takeo
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Mizuyama, Yoko
    Sunami, Takeshi
    Tezuka, Kenji
    Yamagata, Shigehito
    Ishikawa, Tetsuro
    Kudoh, Shinzoh
    Takada, Minoru
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2019, 39 (04) : 2053 - 2059
  • [48] Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
    Rupert Bartsch
    Anna Sophie Berghoff
    Julia Furtner
    Maximilian Marhold
    Elisabeth Sophie Bergen
    Sophie Roider-Schur
    Angelika Martina Starzer
    Heidrun Forstner
    Beate Rottenmanner
    Karin Dieckmann
    Zsuzsanna Bago-Horvath
    Helmuth Haslacher
    Georg Widhalm
    Aysegül Ilhan-Mutlu
    Christoph Minichsdorfer
    Thorsten Fuereder
    Thomas Szekeres
    Leopold Oehler
    Birgit Gruenberger
    Christian F. Singer
    Ansgar Weltermann
    Rainer Puhr
    Matthias Preusser
    Nature Medicine, 2022, 28 : 1840 - 1847
  • [49] Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer
    Katsuhiko Nakatsukasa
    Hiroshi Koyama
    Yoshimi Oouchi
    Seiichi Imanishi
    Naruhiko Mizuta
    Kouichi Sakaguchi
    Yoshifumi Fujita
    Aya Imai
    Akiko Okamoto
    Asako Hamaoka
    Mari Soushi
    Ikuya Fujiwara
    Tatsuya Kotani
    Takayuki Matsuda
    Kenichirou Fukuda
    Midori Morita
    Sadao Kawakami
    Yayoi Kadotani
    Eiichi Konishi
    Akio Yanagisawa
    Mariko Goto
    Kei Yamada
    Tetsuya Taguchi
    Breast Cancer, 2017, 24 : 92 - 97
  • [50] Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Oouchi, Yoshimi
    Imanishi, Seiichi
    Mizuta, Naruhiko
    Sakaguchi, Kouichi
    Fujita, Yoshifumi
    Imai, Aya
    Okamoto, Akiko
    Hamaoka, Asako
    Soushi, Mari
    Fujiwara, Ikuya
    Kotani, Tatsuya
    Matsuda, Takayuki
    Fukuda, Kenichirou
    Morita, Midori
    Kawakami, Sadao
    Kadotani, Yayoi
    Konishi, Eiichi
    Yanagisawa, Akio
    Goto, Mariko
    Yamada, Kei
    Taguchi, Tetsuya
    BREAST CANCER, 2017, 24 (01) : 92 - 97
12345